Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

BACKGROUND: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study was to determine the effect of tofacitinib on patient-reported ou...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Gastroenterol
Autors principals: Panés, Julián, Su, Chinyu, Bushmakin, Andrew G, Cappelleri, Joseph C, Mamolo, Carla, Healey, Paul
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323227/
https://ncbi.nlm.nih.gov/pubmed/25651782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0239-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars